We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Advanced BioMatrix Acquires HyStem® from Lineage Cell Therapeutics


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Advanced BioMatrix Acquires HyStem® from Lineage Cell Therapeutics"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Advanced BioMatrix has acquired the HyStem® line of products from Lineage Cell Therapeutics – previously BioTime/ESI Bio/Glycosan.

HyStem® kits are based on thiolated hyaluronic acid technology. With HyStem®, researchers can create customizable 3D hydrogels for culturing cells whose natural environment is rich in hyaluronic acid.

This acquisition includes the transfer of technology, intellectual property, know-how and assets for the manufacturing and sale of HyStem® products for research and development purposes. ABM and LTC are working closely together to ensure an efficient and seamless handover of the manufacturing, testing and distribution of products to users of the HyStem® products.

ABM began providing and distributing HyStem® products on October 1, 2019. ABM plans to manufacture and supply the full product line including HyStem®, HyStem-C® and HyStem-HP® kits, as well as the individual kit components in bulk format.

Advanced BioMatrix plans to implement the following:

  • Production of HyStem® products in state-of-the-art manufacturing facility and cleanrooms.
  • More rigorous quality control testing - rheology, viscosity and additional quality control tests on each batch of material to measure and control the consistency of HyStem® hydrogels. 
  • Stringent manufacturing protocols and specifications to ensure product lot-to-lot consistency.
  • Provide a Certificate of Analysis for each batch of product.
  • Utilization of the Advanced BioMatrix extensive distribution networks to minimize international shipping delays.
Advertisement